Question 1

What are the potential benefits of participating in this trial compared to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) clinical trial (NCT02034552). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from radium-223 dichloride and the other medications?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) clinical trial (NCT02034552). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) clinical trial (NCT02034552). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) clinical trial (NCT02034552). Contact the study team or your healthcare provider for specific answers.

Question 5

How often will I need to visit the clinic during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) clinical trial (NCT02034552). Contact the study team or your healthcare provider for specific answers.

Question 6

What is the expected duration of my participation in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) clinical trial (NCT02034552). Contact the study team or your healthcare provider for specific answers.

What this study is about